ArticleThe British journal of dermatology2020
Health-related quality of life and economic implications of cutaneous T-cell lymphoma.
Article in The British journal of dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Pooled it
- Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.Blood advances · 2021Trial
- Psychological Distress, Symptom Burden and Quality of Life in Patients with Mycosis Fungoides and Sézary Syndrome.Acta dermato-venereologica · 2026Observational
- Adverse events associated with systemic cutaneous T-cell lymphoma therapies: a narrative review.Frontiers in medicine · 2026Review
- Economic burden and health-related quality of life in Chinese patients with mycosis fungoides and Sézary syndrome.Cancer pathogenesis and therapy · 2025Article
- Available questionnaires do not cover important aspects of quality of life of patients with cutaneous T-cell lymphoma: evaluation of the quality of life of Polish patients with cutaneous T-cell lymphoma.Postepy dermatologii i alergologii · 2025Article
- Mental Health Diagnoses in Patients With Mycosis Fungoides and Potential Impact on Oncologic Outcomes.Cancer medicine · 2025Article
- Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway.Investigational new drugs · 2025Article
- Identification of subgroups of early-stage mycosis fungoides patients with increased itch and impaired quality of life.Frontiers in oncology · 2025Article
- A Retrospective Cohort Study to Determine Real-World Treatment Patterns in Patients with Sézary Syndrome in the United States.Oncology and therapy · 2024Article
- Evaluation of Quality of Life and Treatment Satisfaction in Newly Diagnosed Cutaneous T-Cell Lymphoma Patients.Cancers · 2024Article
- Lifestyle, demographic and Skindex measures associated with cutaneous T-cell lymphoma: a single institution cohort study.Archives of dermatological research · 2023Article
- Characteristics associated with quality of life in the early stages of Mycosis Fungoides.Caspian journal of internal medicine · 2023Article
- Article
- Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms.PharmacoEconomics - open · 2022Article
- Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.Dermatology and therapy · 2022Review
- "Alterations in the Skin Microbiota Are Associated With Symptom Severity in Mycosis Fungoides".Frontiers in cellular and infection microbiology · 2022Article
- Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma.The British journal of dermatology · 2021Article
- Quality of Life, Anxiety, and Depression in Patients With Early-Stage Mycosis Fungoides and the Effect of Oral Psoralen Plus UV-A (PUVA) Photochemotherapy on it.Frontiers in medicine · 2020Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
backgroundCutaneous T-cell lymphoma (CTCL) has been associated with considerable physical, psychological and financial burden. However, its impact on health-related quality of life (QoL) and economic costs are not well studied.
objectivesTo measure the QoL impact and financial burden of CTCL.
methodsA cross-sectional survey of 67 patients with CTCL was conducted using the Ontario Health Utilities Index Mark 3 (HUI3) questionnaire. Normative population data (n = 3310) were obtained from the 2002-2003 Joint Canada/United States Survey of Health. Economic cost was estimated using quality-adjusted life-year (QALY) loss derived from HUI3 scores.
resultsPatients with CTCL had significantly lower aggregate HUI3 scores than the general population (0·68 vs. 0·87, P < 0·001). Multivariable regression analysis adjusting for demographics and comorbidities showed CTCL was associated with significantly poorer performance overall (-0·13, 95% CI -0·21 to -0·06, P < 0·001) and in domains of speech (-0·03, 95% CI -0·05 to -0·01, P = 0·01), ambulation (-0·04, 95% CI -0·08 to 0·00, P = 0·03), emotion (-0·07, 95% CI -0·12 to -0·02, P = 0·01), and pain (-0·07, 95% CI -0·13 to -0·01, P = 0·03). These health utility decrements yielded an average loss of 1·48 QALYs per patient. Using a $50 000 per QALY willingness-to-pay threshold, CTCL was associated with an individual lifetime burden of $73 889 and U.S. societal burden of $2·86 billion.
conclusionsThese findings suggest CTCL has a pervasive impact on QoL, comparable with debilitating conditions such as end-stage renal disease. The substantial economic burden of CTCL underscores the potential societal benefit of prompt diagnosis and effective management. What's already known about this topic? Cutaneous T-cell lymphoma is associated with physical, psychological and financial burden. What does this study add? The overall quality-of-life impact of cutaneous T-cell lymphoma has not previously been measured using a generic health utility instrument. In this study, we compare the overall quality-of-life burden of patients with cutaneous T-cell lymphoma with that of other populations and calculate the economic burden of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.